(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 14.94% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 2.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 54.43%.
Exagen's revenue in 2025 is $56,724,000.On average, 1 Wall Street analysts forecast XGN's revenue for 2025 to be $1,173,757,523, with the lowest XGN revenue forecast at $1,173,757,523, and the highest XGN revenue forecast at $1,173,757,523.
In 2026, XGN is forecast to generate $1,364,583,133 in revenue, with the lowest revenue forecast at $1,332,178,784 and the highest revenue forecast at $1,396,987,482.